<DOC>
	<DOC>NCT00777842</DOC>
	<brief_summary>The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.</brief_summary>
	<brief_title>Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Key Patient has discrete de novo lesion of a coronary artery with symptomatic ischemic heart disease Planned treatment of one lesion with a single stent Denovo type A, B1 lesions with a Reference diameter between 3.0 and 3.5mm and a lesion length between 5 and 16mm Key Diabetic (HbA1C &gt;6.0) Platelet count &lt; 100000 cells/mm3 or &gt; 700000 cells/mm3; WBC &lt; 3000 cells/mm3; or a hemoglobin &lt; 10 g/dl Renal dysfunction with creatinine &gt; 2.0 mg/dl Patient has a known predilatation ejection fraction (EF) less than forty five (&lt;45%) Myocardial infarction (MI) less than 3 months prior to intervention Patient has type B2, C lesion Reference artery diameter &lt;3.0 or &gt;3.6 mm Target lesion length &lt; 5mm and &gt;16 mm Other stenosis &gt;50% in target vessel Known hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine, or cobalt chromium, or a sensitivity to contrast agent that, in the opinion of the investigator, cannot be adequately premedicated.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>